364 related articles for article (PubMed ID: 24745671)
1. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G; Metcalfe DD; Olivera A
Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
[TBL] [Abstract][Full Text] [Related]
2. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
5. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
6. Mastocytosis: advances in diagnosis and treatment.
Hungness SI; Akin C
Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
[TBL] [Abstract][Full Text] [Related]
7. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.
Chaix A; Lopez S; Voisset E; Gros L; Dubreuil P; De Sepulveda P
J Biol Chem; 2011 Feb; 286(8):5956-66. PubMed ID: 21135090
[TBL] [Abstract][Full Text] [Related]
9. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilia in mast cell disease.
Kovalszki A; Weller PF
Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
[TBL] [Abstract][Full Text] [Related]
11. Mast cell disorders: A framework of allergy and hematology symptoms leading to personalized treatments.
Castells MC
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):403-404. PubMed ID: 34593102
[No Abstract] [Full Text] [Related]
12. Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
Palam LR; Mali RS; Ramdas B; Srivatsan SN; Visconte V; Tiu RV; Vanhaesebroeck B; Roers A; Gerbaulet A; Xu M; Janga SC; Takemoto CM; Paczesny S; Kapur R
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467326
[TBL] [Abstract][Full Text] [Related]
13. Bone Marrow Expression of Mast Cell Disorders.
Sánchez-Muñoz L; Henriques AF; Alvarez-Twose I; Matito A
Immunol Allergy Clin North Am; 2018 Aug; 38(3):379-395. PubMed ID: 30007458
[TBL] [Abstract][Full Text] [Related]
14. c-Kit and c-kit mutations in mastocytosis and other hematological diseases.
Boissan M; Feger F; Guillosson JJ; Arock M
J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis.
Dror Y; Leaker M; Caruana G; Bernstein A; Freedman MH
Br J Haematol; 2000 Mar; 108(4):729-36. PubMed ID: 10792276
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
17. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
18. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.
Gerbaulet A; Wickenhauser C; Scholten J; Peschke K; Drube S; Horny HP; Kamradt T; Naumann R; Müller W; Krieg T; Waskow C; Hartmann K; Roers A
Blood; 2011 Feb; 117(6):2012-21. PubMed ID: 21148330
[TBL] [Abstract][Full Text] [Related]
19. Mastocytosis.
Brockow K; Metcalfe DD
Chem Immunol Allergy; 2010; 95():110-124. PubMed ID: 20519885
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
Bibi S; Arock M
Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
